AI Tool SCORPIO Predicts Cancer Immunotherapy Response Using Routine Blood Tests

AI Model SCORPIO Revolutionizes Cancer Immunotherapy Prediction

Researchers from Memorial Sloan Kettering Cancer Center (MSK) and the Tisch Cancer Institute at Mount Sinai have developed a groundbreaking artificial intelligence tool called SCORPIO that could transform cancer treatment decisions worldwide 1

1

2

2

. This innovative model uses routine blood tests and clinical data to predict patient responses to immune checkpoint inhibitors, a type of immunotherapy.

Advantages Over Current Methods

SCORPIO offers several advantages over existing prediction methods:

1. Accessibility: Unlike current FDA-approved biomarkers that require tumor samples and expensive genomic testing, SCORPIO relies on widely available clinical data and routine blood tests 1

   1

   2

   2

   .

2. Improved Accuracy: The model outperforms currently used tests in predicting patient outcomes 1

   1

   2

   2

   3

   3

   .

3. Cost-Effectiveness: By using readily available data, SCORPIO could reduce healthcare costs and improve access to care 1

   1

   2

   2

   .

Development and Validation

The SCORPIO model was developed using a comprehensive approach:

1. Initial Development: Data from over 2,000 MSK patients across 17 cancer types was used to train the model 1

   1

   2

   2

   3

   3

   .

2. Extensive Testing: The model was validated using:

   • 2,100 additional MSK patients
   • Nearly 4,500 patients from 10 global phase 3 clinical trials
   • 1,200 patients from Mount Sinai 1

     1

     2

     2

     3

     3

3. Diverse Dataset: In total, the study included nearly 10,000 patients across 21 different cancer types, representing the largest dataset in cancer immunotherapy to date 1

   1

   2

   2

   3

   3

   .

Technical Approach

SCORPIO employs ensemble machine learning, combining several tools to identify patterns in clinical data from blood tests and treatment outcomes 1

1

2

2

. The model uses data from complete blood count and comprehensive metabolic profile tests, which are routinely performed in clinics worldwide 1

1

2

2

3

3

.

Potential Impact

Dr. Luc Morris, co-senior author of the study, emphasizes the importance of patient selection for immunotherapy: "Immune checkpoint inhibitors are a very powerful tool against cancer, but they don't yet work for most patients. These drugs are expensive, and they can come with serious side effects" 1

1

2

2

3

3

.

By improving prediction accuracy, SCORPIO could help:

1. Enhance treatment decisions
2. Reduce unnecessary side effects
3. Lower healthcare costs
4. Increase equitable access to care 1

   1

   2

   2

   3

   3

Future Steps

The research team plans to:

1. Collaborate with hospitals and cancer centers globally to further test and optimize the model 1

   1

   2

   2

   3

   3

   .
2. Develop a user-friendly interface for clinicians to access the tool easily 1

   1

   2

   2

   3

   3

   .

As this AI-driven approach continues to evolve, it has the potential to significantly improve cancer care by enabling more personalized and effective treatment strategies for patients worldwide.